Venous Thromboembolism Clinical Trial
Official title:
Single Session Percutaneous Mechanical Thrombectomy for the Treatment of Ilio-femoral Deep Vein Thrombosis: A Preliminary Evaluation
Venous thromboembolism (VTE) is a common condition that occurs when a clot develops in one
of your veins. It affects 5% of the population and is the third most common circulatory
condition after heart attack and stroke. People who experience a clot in their vein can have
significant long term problems with swelling and discomfort. The investigators call this
post thrombotic syndrome (PTS). They can also be at increased risk of having another clot
occur. People who have ilio-femoral clots are more likely to have more severe leg swelling
and pain than those who have clots in smaller veins. They are also more likely to have
problems returning to their normal daily routines and may need more hospital visits.
The current standard of care involves treating patients with anticoagulants (blood thinners)
because it has a low risk of bleeding risk and is inexpensive. Blood thinners prevent the
clot from growing bigger while your own body dissolves the clot over time.
The type of clot you have is the most severe form of DVT. Some experts advise early removal
of the clot - resulting in symptom relief sooner and possibly reducing the risk of PTS. This
is in addition to the standard treatment with blood thinners.
There are currently two options for physically removing these clots. One method involves
placing an intravenous catheter into your leg and injecting medication directly where the
clot is situated. This dissolves the clot. This method is called Catheter Directed
Thrombolysis (CDT). The second method, Percutaneous Mechanical Thrombectomy (PMT), involves
placing an intravenous catheter into your leg and breaking down the clot mechanically and
suctioning it out of the vein - creating good blood flow again to your leg. Both methods
require injection of contrast dye and a special x-ray machine to see where the clot is and
ensure that the entire clot is removed.
CDT is very expensive and has an increased risk of major bleeding. PMT is much less
expensive and has a lower risk of bleeding. The doctors at The Ottawa Hospital do not
typically recommend CDT, nor do we commonly perform PMT for this patient population here.
The investigators would like to enroll 26 participants with ilio-femoral DVTs and perform
PMT to see if they can achieve better outcomes than for those who have just had our routine
treatment of blood thinners. The investigators are only conducting this study here at The
Ottawa Hospital, General Campus. They will follow the progress of participants for 6 months.
The device the investigators are using (Angiojet Ultra Thrombectomy System) is already
approved by Health Canada for this procedure.
n/a
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05347550 -
Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients
|
N/A | |
Enrolling by invitation |
NCT05794165 -
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
|
Phase 2 | |
Completed |
NCT02379806 -
The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study
|
Phase 3 | |
Recruiting |
NCT03691753 -
Safety and Efficacy Study of Fitaya Vena Cava Filter
|
N/A | |
Completed |
NCT02197416 -
Safety of Dabigatran Etexilate in Blood Clot Prevention in Children
|
Phase 3 | |
Recruiting |
NCT05378035 -
DOAC in Chinese Patients With Atrial Fibrillation
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT01895777 -
Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)
|
Phase 3 | |
Completed |
NCT05897697 -
Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
|
||
Completed |
NCT04736420 -
Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT04736719 -
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT04735523 -
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT02829957 -
RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
|
Phase 2/Phase 3 | |
Completed |
NCT02912234 -
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
|
Phase 1 | |
Completed |
NCT02746185 -
Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
|
Phase 3 | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT02223260 -
Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
|
Phase 2 | |
Completed |
NCT02661568 -
Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES)
|
N/A | |
Completed |
NCT01976988 -
Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery
|
Phase 3 | |
Completed |
NCT01431456 -
Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
|
Phase 3 |